Erytech sets out its stall ahead of NYSE Euronext listing
French biopharma company Erytech Pharma, a company that designs innovative treatments for acute leukemia and other oncology indications with unmet medical needs, says that the French market regulator, AMF, granted its visa no13-166 on April 17, 2013, for the prospectus relative to the listing of Erytech shares on the NYSE Euronext regulated market in Paris.
The company’s major innovation, “tumor starvation,” is an innovative concept based on destroying cancerous cells by eliminating their essential nutritive elements. Using this original approach, Erytech designed and industrialized an innovative technique of starving tumors by encapsulating an enzyme in red blood cells. The membrane of the red blood cell prevents any unwanted interaction with the patient’s body. This considerably minimises any side effects for the patient.
A first targeted market estimated at 1 billion euros: acute leukemia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze